[1]BRAY FREDDIE,LAVERSANNE MATHIEU,SUNG HYUNA,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2024,74(3):229-263.
[2] BUKAVINA LAURA,BENSALAH KARIM,BRAY FREDDIE,et al.Epidemiology of renal cell carcinoma:2022 ipdate［J］.European Urology,2022,82(5):529-542.
[3] YAN XQ,YE MJ,ZOU Q,et al.Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma:RENOTORCH,a randomized,open-label,phase III study［J］.Annals of Oncology,2024,35(2):190-199.
[4] VIOLA J CHEN,HERNANDEZ-MEZA,PRASHASTI AGRAWAL,et al.Time on therapy for at least three months correlates with overall survival in metastatic renal cell carcinoma［J］.Cancers,2019,11(7):1000.
[5] FENG Q,YANG Y,REN KDet al.Broadening horizons:the multifaceted functions of ferroptosis in kidney diseases［J］.International Journal of Biological Sciences,2023,19(12):3726-3743.
[6] CHEN X,LI JB,KANG R,et al.Ferroptosis:machinery and regulation［J］.Autophagy,2021,17(9):2054-2081.
[7] ZHANG YY,NI ZHI J,ELAM ELNUR,et al.Juglone,a novel activator of ferroptosis,induces cell death in endometrial carcinoma Ishikawa cells［J］.Food & Function,2021,12(11):4947-4959.
[8] BASULI DEBARGHA,TESFAY LIA,DENG ZHIYONG,et al.Iron addiction:A novel therapeutic target in ovarian cancer［J］.Oncogene,2017,36(29):4089-4099.
[9] ELING NILS,REUTER LUKAS,HAZIN JOHN,et al.Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells［J］.Oncoscience,2015,2(5):517-532.
[10] GREENSHIELDS AL,SHEPHERD TG,HOSKIN DW.Contribution of reactive oxygen species to ovarian cancer cell growth arrest and killing by the anti-malarial drug artesunate:Impact of artesunate on ovarian cancer［J］.Molecular Carcinogenesis,2017,56(1):75-93.
[11] LEI GUANG,ZHUANG LI,GAN BOYI.Targeting ferroptosis as a vulnerability in cancer［J］.Nature Reviews Cancer,2022,22(7):381-396.
[12] FENG HUIZHONG,SCHORPP KENJI,JIN JENNY,et al.Transferrin receptor is a specific ferroptosis marker［J］.Cell Reports,2020,30(10):3411-3423.e7.
[13] LIANG DEGUANG,MINIKES ALEXANDER M,JIANG XUEJUN.Ferroptosis at the intersection of lipid metabolism and cellular signaling［J］.Molecular Cell,2022,82(12):2215-2227.
[14] LE POPE,SJ DIXON.Regulation of ferroptosis by lipid metabolism［J］.Trends in Cell Biology,2023,33(12):1077-1087.
[15] LIU Y,WAN YC,JIANG Y,et al.GPX4:The hub of lipid oxidation,ferroptosis,disease and treatment［J］.Biochimica Et Biophysica Acta Reviews on Cancer,2023,1878(3):188890.
[16] DOLL SEBASTIAN,FREITAS FP,SHAH RON,et al.FSP1 is a glutathione-independent ferroptosis suppressor［J］.Nature,2019,575(7784):693-698.
[17] MAO C,LIU XG,ZHANG YL,et al.DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer［J］.Nature,2021,593(7860):586-590.
[18] KRAFT VN,BEZJIAN CT,PFEIFFER SUSANNE,et al.GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling［J］.ACS Central Science,2020,6(1):41-53.
[19] ZEITLER LEONIE,FIORE ALESSANDRA,MEYER CLAUDIA,et al.Anti-ferroptotic mechanism of IL4i1-mediated amino acid metabolism［J］.eLife,2021,10:e64806.
[20] YANG WAN SEOK,SRIRAMARATNAM ROHITHA,WELSCH MATTHEW E,et al.Regulation of ferroptotic cancer cell death by GPX4［J］.Cell,2014,156(1):317-331.
[21] LI JH,ZHENG SJ,FAN YM,et al.Emerging significance and therapeutic targets of ferroptosis:a potential avenue for human kidney diseases［J］.Cell Death & Disease,2023,14(9):628.
[22] ZHANG YL,SHI JJ,LIU XG,et al.BAP1 links metabolic regulation of ferroptosis to tumour suppression［J］.Nature Cell Biology,2018,20(10):1181-1192.
[23] AFFAR EL BACHIR,CARBONE MICHELE.BAP1 regulates different mechanisms of cell death［J］.Cell Death & Disease,2018,9(12):1151.
[24] JIANG LE,KON NING,LI TONGYUAN,et al.Ferroptosis as a p53-mediated activity during tumour suppression［J］.Nature,2015,520(7545):57-62.
[25] ZHANG LONG,HOBEIKA CHARBEL S,KHABIBULLIN DAMIR,et al.Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11［J］.Proceedings of the National Academy of Sciences,2022,119(28):e2122840119.
[26] KERINS MJ,MILLIGAN JOHN,WOHLSCHLEGEL JA,et al.Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction［J］.Cancer Science,2018,109(9):2757-2766.
[27] YANG WEN HSUAN,DING CHIEN KUANG CORNELIA,SUN TIANAI,et al.The Hippo pathway effector TAZ regulates ferroptosis in renal cell carcinoma［J］.Cell Reports,2019,28(10):2501-2508.e4.
[28] LAI YC,ZENG T,LIANG XF,et al.Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy［J］.Cancer Cell International,2019,19:221.
[29] YU R,ZHOU YF,SHI SF,et al.Icariside II induces ferroptosis in renal cell carcinoma cells by regulating the miR-324-3p/GPX4 axis［J］.Phytomedicine,2022,102:154182.
[30] HUANG Z,GAN S,ZHUANG X,et al.Artesunate inhibits the cell growth in colorectal cancer by promoting ROS-dependent cell senescence and autophagy［J］.Cells,2022,11(16):2472.
[31] MA ZC,CHEN WJ,LIU YD,et al.Artesunate Sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy［J］.Autophagy,2024,20(3):541-556.
[32] EFFERTH THOMAS.From ancient herb to modern drug:Artemisia annua and artemisinin for cancer therapy［J］.Seminars in Cancer Biology,2017,46:65-83.
[33] LEE HYE MIN,MOON AREE.Amygdalin regulates apoptosis and adhesion in Hs578T triple-negative breast cancer cells［J］.Biomolecules & Therapeutics,2016,24(1):62-66.
[34] MARKOWITSCH SASCHA D,SCHUPP PATRICIA,LAUCKNER JULIA,et al.Artesunate inhibits growth of sunitinib-resistant renal cell carcinoma cells through cell cycle arrest and induction of ferroptosis［J］.Cancers,2020,12(11):3150.
[35] KANG RUI,KROEMER GUIDO,TANG DAOLIN.The tumor suppressor protein p53 and the ferroptosis network［J］.Free Radical Biology & Medicine,2019,133:162-168.
[36] XIAO HX,XU XZ,DU LY,et al.Lycorine and organ protection:Review of its potential effects and molecular mechanisms［J］.Phytomedicine,2022,104:154266.
[37] QI J,MENG M,LIU J,et al.Lycorine inhibits pancreatic cancer cell growth and neovascularization by inducing Notch1 degradation and downregulating key vasculogenic genes［J］.Biochemical Pharmacology,2023,217:115833.
[38] LI Z,ZHOU Q,LIU X,et al.Lycorine upregulates the expression of RMB10,promotes apoptosis and inhibits the proliferation and migration of cervical cancer cells［J］.International Journal of Molecular Medicine,2022,50(6):145.
[39] DU Y,ZHAO HC,ZHU HC,et al.Ferroptosis is involved in the anti-tumor effect of lycorine in renal cell carcinoma cells［J］.Oncology Letters,2021,22(5):781.
[40] HAN SHANGTING,LIN FANGYOU,QI YUCHENG,et al.HO-1 contributes to luteolin-triggered ferroptosis in clear cell renal cell carcinoma via increasing the labile iron pool and promoting lipid peroxidation［J］.Oxidative Medicine and Cellular Longevity,2022,2022:1-26.
[41] CHEN YH,WU JYUNXUE,YANG SHUN FA,et al.Synergistic combination of luteolin and asiatic acid on cervical cancer in vitro and in vivo［J］.Cancers,2023,15(2):548.
[42] E JUENGEL,A THOMAS,J RUTZ,et al.Amygdalin inhibits the growth of renal cell carcinoma cells in vitro［J］.International Journal of Molecular Medicine,2016,37(2):526-532.
[43] J RUTZ,S MAXEINER,E JUENGEL,et al.Growth and proliferation of renal cell carcinoma cells is blocked by low curcumin concentrations combined with visible light irradiation［J］.International Journal of Molecular Sciences,2019,20(6):1464.
[44] PB GUPTA,TT ONDER,G JIANG,et al.Identification of selective inhibitors of cancer stem cells by high-throughput screening［J］.Cell,2009,138(4):645-659.
[45] ZHOU J,LIU S,WANG Y,et al.Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma［J］.Molecular Cancer,2019,18(1):159.
[46] WANG ZY,ZHANG H,CHENG Q.PDIA4:The basic characteristics,functions and its potential connection with cancer［J］.Biomedicine & Pharmacotherapy,2020,122:109688.
[47] ZOU YL,PALTE MICHAEL J,DEIK AMY A,et al.A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis［J］.Nature Communications,2019,10(1):1617.
[48] B ESCUDIER,T EISEN,WM STADLER,et al.Sorafenib in advanced clear-cell renal-cell carcinoma［J］.The New England Journal of Jedicine,2007,356(2):125-134.
[49] DIXON SCOTT J,PATEL DARPAN N,WELSCH MATTHEW,et al.Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis［J］.eLife,2014,3:e02523.
[50] CHANG K,CHEN Y,ZHANG X,et al.DPP9 stabilizes NRF2 to suppress ferroptosis and induce sorafenib resistance in clear cell renal cell carcinoma［J］.Cancer Research,2023,83(23):3940-3955.
[51] TANG Z,LI J,SHEN Q,et al.Contribution of upregulated dipeptidyl peptidase 9(DPP9) in promoting tumoregenicity,metastasis and the prediction of poor prognosis in non-small cell lung cancer(NSCLC)［J］.International Journal of Cancer,2017,140(7):1620-1632.
[52] GAO R,KALATHUR R,COTO-LLERENA M,et al.YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis［J］.EMBO Molecular Medicine,2021,13(12):e14351.
[53] PARK JEE SOO,KOO KYO CHUL,CHUNG DOO YONG,et al.Visceral adiposity as a significant predictor of sunitinib-induced dose-limiting toxicities and survival in patients with metastatic clear cell renal cell carcinoma［J］.Cancers,2020,12(12):3602.
[54] WANG Q,GAO S,SHOU Y,et al.AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis［J］.International Journal of Biological Sciences,2023,19(4):1266-1283.
[55] GAN B.ACSL4,PUFA,and ferroptosis:new arsenal in anti-tumor immunity［J］.Signal Transduction and Targeted Therapy,2022,7(1):128.
[56] YANGYUN WANG,GUOWEI SHI,SHUFEN SHI,et al.Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma［J］.Gene,2022,809:145992.
[57] HAO JF,CHEN QG,FENG YM,et al.Combination treatment with FAAH inhibitors/URB597 and ferroptosis inducers significantly decreases the growth and metastasis of renal cell carcinoma cells via the PI3K-AKT signaling pathway［J］.Cell Death & Disease,2023,14(4):247.
[58] S JAISWAL,SR AYYANNAN.Anticancer potential of small-molecule inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase［J］.Chem Med Chem,2021,16(14):1-17.
[59] D FIORE,MC PROTO,S PISANTI,et al.Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells［J］.Cancer Biology & Therapy,2016,17(8):849-858.
[60] N VAN EGMOND,VM STRAUB,M VAN DER STELT.Targeting endocannabinoid signaling:FAAH and MAG lipase inhibitors［J］.Annual Review of Pharmacology and Toxicology,2021,6:1-23.
[61] NI WENJUN,LI YONGXIANG,LIANG LINGXIA,et al.Tumor microenvironment-responsive nanodrug for clear-cell renal cell carcinoma therapy via triggering waterfall-like cascade ferroptosis［J］.Journal of Biomedical Nanotechnology,2022,18(2):327-342.
[62] LI FY,LU JX,KONG XQ,et al.Dynamic nanoparticle assemblies for biomedical applications［J］.Advanced Materials,2017,29(14):1605897.
[63] LIU B,HU F,ZHANG JF,et al.A biomimetic coordination nanoplatform for controlled encapsulation and delivery of drug-gene combinations［J］.Angewandte Chemie(International Ed.in English),2019,58(26):8804-8808.
[64] LIU JJ,WU M,PAN YT,et al.Biodegradable nanoscale coordination polymers for targeted tumor combination therapy with oxidative stress amplification［J］.Advanced Functional Materials,2020,30(13):1908865.
[65] LIU Z,LI T,HAN F,et al.A cascade-reaction enabled synergistic cancer starvation/ROS-mediated/chemo-therapy with an enzyme modified Fe-based MOF［J］.Biomaterials Science,2019,7(9):1-10.
[66] HUANG Y,JC HSU,H KOO,et al.Repurposing ferumoxytol:Diagnostic and therapeutic applications of an FDA-approved nanoparticle［J］.Theranostics,2022,12(2):796-816.
[67] LIANG H,WU X,ZHAO G,et al.Renal clearable ultrasmall single-crystal Fe nanoparticles for highly selective and effective ferroptosis therapy and immunotherapy［J］.Journal of the American Chemical Society,2021,143(38):15812-15823.